Kiniksa Pharmaceuticals, Ltd. total revenue, net income and dynamics of changes in US dollar today
Kiniksa Pharmaceuticals, Ltd. current income and income for the latest reporting periods. Kiniksa Pharmaceuticals, Ltd. net revenue for today is 0 $. Net income, revenue and dynamics - the main financial indicators of Kiniksa Pharmaceuticals, Ltd.. The financial schedule of Kiniksa Pharmaceuticals, Ltd. consists of three charts of the main financial indicators of the company: total assets, net revenue, net income. The financial report schedule from 31/12/2018 to 31/03/2021 is available online. A graph of the value of all Kiniksa Pharmaceuticals, Ltd. assets is presented in green bars.
Report date
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and
Change (%)
Comparing current quartal report this year to quartal report last year.
Dates of Kiniksa Pharmaceuticals, Ltd. finance reports: 31/12/2018, 31/12/2020, 31/03/2021. The dates of financial statements are strictly regulated by law and financial statements. The latest date of the financial report of Kiniksa Pharmaceuticals, Ltd. is 31/03/2021. Operating income Kiniksa Pharmaceuticals, Ltd. is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Kiniksa Pharmaceuticals, Ltd. is -49 283 000 $
Net income Kiniksa Pharmaceuticals, Ltd. is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Kiniksa Pharmaceuticals, Ltd. is -49 484 000 $ Current assets Kiniksa Pharmaceuticals, Ltd. is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Kiniksa Pharmaceuticals, Ltd. is 275 564 000 $ Total assets Kiniksa Pharmaceuticals, Ltd. refers to the total amount of assets owned by a person or entity. Total assets Kiniksa Pharmaceuticals, Ltd. is 311 158 000 $
Current cash Kiniksa Pharmaceuticals, Ltd. - the sum of all of the cash a company has on the date of report. Current cash Kiniksa Pharmaceuticals, Ltd. is 119 856 000 $
31/03/2021
31/12/2020
30/09/2020
30/06/2020
30/09/2019
30/06/2019
31/03/2019
31/12/2018
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
-
-
-
-
-
-
-
-
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
-
-
-
-
-
-
-
-
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
-
-
-
-
-
-
-
-
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
-
-
-
-
-
-
-
-
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
-49 283 000 $
-52 898 000 $
-43 218 000 $
-31 860 000 $
-30 446 000 $
-39 289 000 $
-67 647 000 $
-44 135 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
-49 484 000 $
-53 657 000 $
-43 836 000 $
-37 469 000 $
-27 058 000 $
-37 191 000 $
-65 821 000 $
-42 580 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
28 683 000 $
38 552 000 $
31 048 000 $
21 931 000 $
21 622 000 $
30 400 000 $
58 830 000 $
35 901 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
49 283 000 $
52 898 000 $
43 218 000 $
31 860 000 $
30 446 000 $
39 289 000 $
67 647 000 $
44 135 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
275 564 000 $
333 249 000 $
378 413 000 $
264 493 000 $
268 340 000 $
296 458 000 $
334 956 000 $
313 750 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
311 158 000 $
349 464 000 $
384 413 000 $
271 441 000 $
281 805 000 $
308 137 000 $
346 159 000 $
321 965 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
119 856 000 $
114 038 000 $
85 874 000 $
123 456 000 $
68 809 000 $
82 810 000 $
82 629 000 $
71 976 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
-
-
-
-
27 560 000 $
30 178 000 $
36 892 000 $
42 554 000 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
-
-
-
-
-
-
-
-
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
-
-
-
-
29 894 000 $
32 940 000 $
39 640 000 $
42 698 000 $
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
-
-
-
-
10.61 %
10.69 %
11.45 %
13.26 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
270 696 000 $
311 935 000 $
358 509 000 $
250 416 000 $
251 911 000 $
275 197 000 $
306 519 000 $
279 267 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
-
-
-
-
-29 267 000 $
-41 676 000 $
-63 256 000 $
-27 638 000 $
Last revenue report of Kiniksa Pharmaceuticals, Ltd. was 31/03/2021. According to last financial report total revenue in Kiniksa Pharmaceuticals, Ltd. was 0 US dollar and changed by 0% since last year. Net income in Kiniksa Pharmaceuticals, Ltd. was -49 484 000 $ in last quartal, net income changes to 0%.
